Molecular Identification of Simian Virus 40 Infection in Healthy Italian Subjects by Birth Cohort

VALENTINA PARACCHINI,1 SEYMOUR GARTE,2 PAOLA PEDOTTI,1 FRANCESCA POLI,3 SARA FRISON,3 AND EMANUELA TAIOLI1

Simian virus SV40, an oncogenic virus in rodents, was accidentally transmitted to humans through the Poliovirus vaccine during the years 1955 to 1963. If the vaccination program were the major source of human infection, then differences in SV40 infection rates by cohort of birth should be observed. The aim of this study was to address this issue. In 134 healthy Italian Caucasian subjects, 15 DNA samples were positive for SV40 by nested polymerase chain reaction and DNA sequencing. The prevalence of genomic infection did not differ across cohorts of birth from 1924 to 1983, however DNA sequencing revealed viral strain differences in individuals born before 1947 and after 1958. While horizontal transmission following the introduction of the polio vaccine could explain the presence of SV40 DNA in younger people, our results also suggest the possibility that other sources of the virus may also be involved in human SV40 infection.

Online address: http://www.molmed.org
doi: 10.2119/2005-00007.Taioli

INTRODUCTION

Simian virus SV40, an oncogenic virus in rodents, has been detected in human tumors and tissues at variable frequencies. The virus was inadvertently transmitted to humans through the Poliovirus vaccine between 1955 and 1963 in the United States (1). Epidemiological studies do not indicate an increased incidence of cancer related to such contamination (2,3), and the role of SV40 sequences in human tumorigenesis remains controversial. Some of the controversy is due to methodological issues related to detection of the virus (4). High levels of SV40 viral infection have been reported in some tumors, and from some laboratories (1,5), whereas others have not found consistent evidence for widespread SV40 infection and propose that laboratory contamination, hypersensitivity of the polymerase chain reaction (PCR) or cross reactivity of the virus with other common viruses are responsible for the positive results (6,7). At present, there is, therefore, no clear consensus as to the actual degree of SV40 positivity in either human tumors or even in human blood and other nondiseased tissues. Studies that have investigated the presence of SV40 by DNA sequence or serological methods have found infection rates varying from 0 to more than 20% (8–13). One of the unresolved questions involves the discovery of SV40 DNA in tumors of persons born after or long before the polio vaccination program of the early 1960s. Such findings have raised the possibility that SV40 infection has been transmitted horizontally among the human population, and therefore can be found in people never directly exposed to the vaccine (14,15). To address the issue of SV40 infection as a direct result of vaccination as opposed to transmission by other routes, we have examined blood DNA from individuals ranging in age from 26 to 77, born between 1924 and 1983. The presence of SV40 DNA, determined by PCR and DNA sequencing, was analyzed according to cohort of birth. No such study of the presence of SV40 genomes in subjects without cancer by cohort of birth has been performed so far.

MATERIALS AND METHODS

We studied 134 solid organ donors of Caucasian Italian origin (56.7% males), whose anonymous DNA, isolated from peripheral blood lymphocytes, was stored in the repository of the North Italian Transplant Reference Center located in the Policlinico Hospital of Milano, Italy, since 1972. No identifying linkers exist for these samples. Informed consent for organ donation and evaluation of organ safety, as required by Italian law, was obtained by family members at the time of organ donation. The program of solid organ donation was approved by the Hospital Ethical Committee. A random sample of these DNAs, stratified by cohort of birth, was extracted from the whole set of DNA samples currently stored (n = 10707). None of the subjects were clinically affected by cancer at the time of donation. DNA was isolated from blood samples using the method of Gustincich et al. (16). DNA concentration was measured by spectrophotometry, and ranged from 100 ng/µL to 450 ng/µL.

PCRs were performed to determine the presence of SV40 sequences in our samples. Negative and positive controls were included in all sets of reactions. The pBR3V (ATCC 45019, from G. Khoury), plasmid, containing the entire genome of reference strain SV40–776, was used as the positive control in PCR amplification. DNA (1 µg) was amplified in a total volume of 50 µL. The regulatory region of the SV40 viral genome was analyzed by 2 nested PCRs, using the primer set RA3 (GCGTGACAGCCG-1Unit of Molecular and Genetic Epidemiology, Fondazione Policlinico IRCCS, Milano, Italy; 2Genetics Research Institute ONLUS, Milano, Italy; and 3Centro Trasfusionale ed Immunologia dei Trapianti, Fondazione Policlinico IRCCS, Milano, Italy
Table 1. Presence of sv40 genomic regions in healthy subjects according to cohort of birth

| Birth cohort    | Nr  | Males (%)  | PCR | Sequencinga | Percent (95% CI) |
|-----------------|-----|------------|-----|-------------|-----------------|
| 1924-1933       | 14  | 6 (42.9)   | 3   | 3/3 (2F, 1M) | 21.4 (0-42.9)   |
| 1934-1943       | 34  | 17 (50.0)  | 5   | 5/5 (3F, 2M) | 14.7 (2.8-26.6)|
| 1944-1953       | 25  | 10 (40.0)  | 1   | 1/1 (1F)    | 4.0 (0-11.7)    |
| 1954-1963       | 19  | 15 (78.9)  | 3   | 3/3 (1F, 2M)| 15.8 (3-32.2)  |
| 1964-1973       | 17  | 11 (64.7)  | 1   | 1/1 (1M)    | 5.9 (0-17.1)    |
| 1974-1983       | 25  | 17 (68.0)  | 3   | 2/3 (1F, 1M)| 8.0 (0-18.6)    |
| Total           | 134 | 76 (56.7)  | 15  | 15/16 (8F, 7M)| 11.2 (5.9-16.5)|

Chi square = 4.33, NS = not significant.

aChi-square test for trend.

RESULTS

Sixteen DNA samples of 134 investigated were positive for SV40 using PCR, and 15 of these (11.2%, 95% CI: 5.9% to 16.5%) were confirmed by sequencing. One sample was positive by PCR but not by sequencing. One of the positive samples proved to be archetypal, containing only one 72-bp repeat, whereas the other fourteen were nonarchetypal, with two 72-bp repeats. The frequency of positive samples by birth date cohort is shown in Table 1, ranging from 4.0% to 21.4% without statistically significant differences across cohorts. The positive samples belonged to 7 out of 76 male subjects (9.2%, 95% CI: 2.7% to 29.5%), and to 8 of 58 female subjects (13.8%, 95% CI: 4.9% to 22.7%). Examination of the sequence data revealed 3 variants of SV40 DNA sequence. Six of the samples had the same sequence as strain SV40-776 (SV40ITVAR1); Variant 2 (SV40-ITVAR2) included 4 samples with an insertion of A at position 56, a deletion at position 159, and a C-to-T base substitution at position 178. Another variant (SV40-ITVAR3) included 4 samples with a G-to-A base substitution at position 65, and the same C-to-T base substitution at position 178. Other mutations were found in some of the samples, which are therefore labeled as substrains (VAR3A, etc.) as indicated in Table 2. None of the samples showed polymorphism at position 5209, and in none of the samples could the TAG region be amplified. None of the sequence variants matched any of the previously published sequence variations in the regulatory region (18–21), nor any of those listed in GENBANK. Therefore, definitive strain identification is not possible. Strikingly, the distribution of these sequence variants was not uniform across birth cohorts, with all of the 6 ITVAR1 samples belonging to persons born after 1958, whereas the samples with SV40 ITVAR2 and ITVAR3 variants were all from subjects born before 1947 (Table 2), where a more diverse mixture of variants is observed. None of the samples showed sequence homology to either JCV or BKV sequences (including the single sample that was negative by DNA sequencing).

DISCUSSION

The present study did not show any significant difference in SV40 infection rates according to year of birth. Poliovirus vacci-
nation was a requirement for admission to both nursery and primary school in Italy starting from 1959, and it became mandatory within the 1st year of life in 1966. Therefore, if the only source of the infection were polio vaccination, SV40 positive samples should be found to a larger degree in the cohort of subjects born between 1953 and 1963. In our study, 19 subjects were born in this time frame, and 3 of them were positive for SV40, with a prevalence of infection (14.3%, 95% C.I.: 0% to 34.7%) similar to that observed in subjects born in previous or subsequent years, indicating no difference in the frequency of infection according to cohort of birth. One study (7) of SV40 infection in normal blood also found no differences in rate between persons born before (4.3%) and after (8.2%) 1962. However, these authors suggest all of the SV40 serological positivity was due to cross reactivity to antibodies to the common human JC and BK viruses (7,22).

Although the past few years have witnessed a large number of publications on the presence of SV40 sequences in human tumors (23–27), surprisingly little information exists on the proportion of SV40 infection in the blood of healthy individuals. This report of SV40 DNA in 134 persons represents the largest such study in a control population done to date. The published frequency of SV40 DNA in normal tissues or in people without cancer is quite variable. In Italians, 1 group has found frequencies of 13% (28), 23% (29), and 29% (11) in blood, and 45% (29) in sperm, whereas another Italian group has failed to find any positive control samples among 84 examined (30,31). We found a frequency of SV40 positives of 11%, similar to the average of that found in other studies. The frequency of infection was similar in females and in males. We were unable to find positive subjects for the Tag COOH region of SV40. A possible explanation could be that the Tag COOH region was analyzed by a less sensitive approach than that used for the regulatory region.

It is supposed that SV40 viral infection entered the human population through poliovirus vaccination in Italy during the years 1957 to 1963. The vaccination started on a voluntary basis in 1957, and it became mandatory for school admission starting from 1959. The vaccine used at that time was killed Salk vaccine type produced in Italy, Belgium, and United States, whereas the live attenuated Sabin vaccine was introduced in Italy starting from 1964. Although cytopathic tests were routinely performed on the vaccine stocks, it cannot be excluded that some degree of contamination did exist. The explanation for the existence of SV40 DNA in persons too old or too young to have been directly inoculated with the vaccine is horizontal transmission of the virus from the cohort (born between 1953 and 1961) that was inoculated (14,15). Our results are consistent with this interpretation in that we did find SV40 DNA in people who were not inoculated. However, it is puzzling that the rate of infection is not higher in those who could have been directly inoculated than in people whose exposure was due to transmission. While preliminary, our results on sequence variation among the 15 positive samples are consistent with findings of natural sequence variation in the regulatory region of SV40 (32). The non-random distribution of the specific variants among birth cohorts calls into question the uniform spread of the virus from a single inoculated cohort. An alternative possibility is that different sources of human SV40 infection might have existed (33), and that while 1 strain present in an adenovirus type 1 vaccine stock spread by horizontal transmission from the inoculated cohort, other strains, found in older people, might have come from these alternative sources. In addition to these hypotheses, a possible explanation could be that ITVAR1 is more transmissible among humans and has gradually become the most prevalent strain in the population studied. Further research in larger cohorts, and from different global regions, is needed to resolve the issue of how and when SV40 infection entered and spread among the human species.

**ACKNOWLEDGMENTS**

We thank Dr. Lucia Fiore from the Superior Institute of Health in Rome for furnishing information on the origin of the Italian vaccine.

---

### Table 2. SV40 sequence variants

| Year of birth | Donation date | Sex | Sequence variant |
|---------------|---------------|-----|-----------------|
| 1928          | 2002          | F   | ITVAR3 (65G-A, 178C-T) |
| 1932          | 2002          | M   | ITVAR2 (56INS-A, 159DEL, 178C-T, 105G-C) |
| 1933          | 2002          | F   | ITVAR2A (56INS-A, 159DEL, 178C-T) |
| 1936          | 2002          | M   | ITVAR3A (65G-A, 178C-T + 141C-A) |
| 1938          | 2002          | F   | ITVAR2 |
| 1939          | 2002          | M   | ITVAR3 |
| 1939          | 2002          | F   | ITVAR3B (65G-A, 178C-T + 105G-C) |
| 1942          | 2003          | F   | ARCHETYPAL, ONE 72 BP REPEAT |
| 1947          | 2003          | F   | ITVAR2 |
| 1958          | 2003          | F   | ITVAR1A (141C-A) |
| 1963          | 2003          | F   | ITVAR1B (DEL28) |
| 1963          | 2003          | M   | ITVAR1 |
| 1972          | 2003          | M   | ITVAR1 |
| 1974          | 2003          | F   | Negative |
| 1977          | 2003          | F   | ITVAR1 |
| 1979          | 2003          | M   | ITVAR1 |
REFERENCES

1. Butel JS, Lednicky JA. (1999) Cell and molecular biology of simian virus 40: implications for human infections and disease. J. Natl. Cancer Inst. 91:119-34.

2. Strickler HD et al. (2003) Trends in US pleural mesothelioma incidence rates following simian virus 40 contamination of early poliovaccines. J. Natl. Cancer Inst. 95:38-45.

3. Shah KV, Nathanson N. (1976) Human exposure to SV40: review and comments. J. Natl. Cancer Inst. 364:1157-66.

4. Shah KV, Galloway DA, Knowles WA, Viscidi RP. (2004) Simian virus 40 (SV40) and human cancer: a review of the serological data. Rev. Med. Virol. 14:231-9.

5. Carter JJ et al. (2003) Lack of serologic evidence for prevalent simian virus 40 infection in humans. J. Natl. Cancer. Inst. 95:38-45.

6. Shah KV, Mendoza S, Konishi T, Miller CW. (2001) Simian virus 40 is present in human lymphoproliferative disorders of HIV- and HIV+ patients. J. Infect. Dis. 180:884-7.

7. Stewart AR, Lednicky JA, Butel JS. (1996) SV40 early region and large T antigen in human brain tumors from northern India. Int. J. Cancer 101:348-52.

8. Vilchez RA et al. (2004) Emergent human pathogen simian virus 40 and its role in cancer. Clin. Microbiol. Rev. 17:495-508.

9. Lednicky JA et al. (1998) Natural isolates of simian virus 40 DNA sequences in common laboratory plasmids. J. Virol. 72:3980-90.

10. Lednicky JA, Arcega RL, Becsagel DJ, Butel JS. (1995) Natural simian virus 40 strains are present in human choroid plexus and ependymoma tumors. Virology 212:710-7.

11. Lopez-Rios F, Illei PB, Rusch V, Ladanyi M. (2004) Evidence against a role for SV40 homologous with SV40 large T antigen in DNA of human brain and bone tumors. Int. J. Cancer 95:1522-30.

12. Procopio A et al. (1998) SV40 expression in human neoplastic and non-neoplastic tissues: perspectives on diagnosis, prognosis and therapy of human malignant mesothelioma. Dev. Biol. Stand. 94:361-7.

13. Martin F et al. (1995) Human brain tumors and simian virus 40. J. Natl. Cancer. Inst. 87:1331.

14. Carbone M et al. (1994) Simian virus 40-like DNA sequences in human pleural mesothelioma. Cancer Res. 54:817-23.

15. Vilchez RA, Butel JS. (2002) Absence of simian virus 40 in human brain tumors from northern India. Int. J. Cancer 101:348-52.

16. Shah KV, Nathanson N. (1976) Human exposure to SV40: review and comments. J. Natl. Cancer Inst. 364:1157-66.

17. Butel JS, Mendoza S, Konishi T, Miller CW. (2001) Simian virus 40 is present in human lymphoproliferative disorders of HIV- and HIV+ patients. J. Infect. Dis. 180:884-7.

18. Lednicky JA et al. (1998) Natural isolates of simian virus 40 DNA sequences in common laboratory plasmids. J. Virol. 72:3980-90.

19. Butel JS, Arcega RL, Becsagel DJ, Butel JS. (1995) Natural simian virus 40 strains are present in human choroid plexus and ependymoma tumors. Virology 212:710-7.

20. Lednicky JA, Arcega RL, Becsagel DJ, Butel JS. (1995) Natural simian virus 40 strains are present in human choroid plexus and ependymoma tumors. Virology 212:710-7.

21. Lednicky JA, Butel JS. (2001) Simian virus 40 regulatory region structural diversity and the association of viral archetypal regulatory regions with human brain tumors. Semin. Cancer Biol. 11:39-47.

22. Knowles WA et al. (2003) Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40. J. Med. Virol. 71:115-23.

23. Vilchez RA, Kozinetz CA, Arington AS, Madsen CR, Butel JS. (2003) Simian virus 40 in human cancers. Am. J. Med. 114(8):675-84.

24. Klein G, Powers A, Croce C. (2002) Association of SV40 with human tumors. Oncogene 21:1141-9.

25. Stewart AR, Lednicky JA, Butel JS. (1996) SV40 early region and large T antigen in human brain tumors from northern India. Int. J. Cancer 101:348-52.

26. Jasani B et al. (2001) Association of SV40 with human tumors. Semin. Cancer Biol. 11:49-61.

27. Shivapukar N et al. (2002) Presence of simian virus 40 DNA sequences in human lymphomas. Lancet. 359:851-2.

28. Lednicky JA et al. (1998) Natural isolates of simian virus 40 DNA sequences in common laboratory plasmids. J. Virol. 72:3980-90.

29. Martini F et al. (1995) Human brain tumors and simian virus 40. J. Natl. Cancer. Inst. 87:1331.

30. Procopio A et al. (1998) SV40 expression in human neoplastic and non-neoplastic tissues: perspectives on diagnosis, prognosis and therapy of human malignant mesothelioma. Dev. Biol. Stand. 94:361-7.

31. Sarnak JH et al. (2004) Phylogenetic analysis of polyomavirus simian virus 40 from monkeys and humans reveals genetic variation. J. Virol. 78:9306-16.

32. Fastag B. (2002) Sewage yields clues to SV40 transmission. JAMA 288:1337-41.